Adoptive Immunotherapy for Cancer Treatment

Adoptive immunotherapy harnesses the patient’s own or donor-derived lymphocytes to target and eradicate malignant cells. Central to this approach are T lymphocytes that are expanded, engineered or selected ex vivo before being reinfused into lymphodepleted hosts. Techniques range from the transfer of tumour-infiltrating lymphocytes to genetically modified T cells bearing chimeric antigen receptors. Prior lymphodepletion enhances engraftment and function by eliminating regulatory and competing immune cells. Once administered, these effector cells proliferate, traffic to tumour sites and mediate cytotoxicity through antigen-specific recognition. The strategy has demonstrated remarkable efficacy in certain haematological malignancies and holds promise for solid tumours, where overcoming immunosuppressive microenvironments remains a key challenge. Recent advances focus on improving specificity, persistence and safety, as well as combining cell therapy with checkpoint blockade or cytokine support to broaden its clinical impact.

Research from Nature Portfolio

Recent studies have elucidated how viral delivery systems can potentiate adoptive T cell responses by reshaping the tumour stroma and activating alarmin pathways. One investigation showed that a replication-competent viral vector engineered to express tumour antigens provokes interleukin-33–driven mobilisation of cytotoxic T lymphocytes, as well as an inflammatory remodelling of fibroblastic stromal cells, thereby sustaining long-term tumour control in melanoma models. Another report detailed a heterologous prime-boost regimen using two distinct arenavirus-based vectors to overcome self-tolerance, yielding tumour-specific CD8+ T cell expansions that abrogate established solid tumours and confer protection against rechallenge. These findings underscore the potential of combining adoptive cell transfer with vector-mediated microenvironmental reprogramming to enhance antitumour efficacy.

Adoptive Immunotherapy for Cancer Treatment publication trend

The graph below shows the total number of articles in adoptive immunotherapy for cancer treatment across all publications each year (not limited to Nature Index journals).

Technical terms

Adoptive immunotherapy: Treatment involving the infusion of immune cells expanded or modified outside the body to fight cancer.

Chimeric antigen receptor (CAR): A synthetic receptor grafted onto T cells to confer specificity for tumour-associated antigens.

Lymphodepletion: Pre-conditioning regimen that reduces native lymphocytes to improve engraftment and function of infused cells.

Alarmins: Endogenous molecules released by stressed or dying cells that activate innate immune pathways and enhance adaptive responses.

Heterologous prime-boost: Sequential vaccination strategy using different vectors to maximise immune responses and bypass vector-specific immunity.

References

1. Viral vector-mediated reprogramming of the fibroblastic tumor stroma sustains curative melanoma treatment. Nature Communications (2021).
2. Heterologous arenavirus vector prime-boost overrules self-tolerance for efficient tumor-specific CD8 T cell attack. Cell Reports Medicine (2021).
3. Transfer of in vitro-expanded naïve T cells after lymphodepletion enhances antitumor immunity through the induction of polyclonal antitumor effector T cells. PLOS ONE (2017).
4. Requirement of Innate Immunity in Tumor‐Bearing Mice Cured by Adoptive Immunotherapy Using Tumor‐Draining Lymph Nodes. Journal of Immunology Research (2015).